SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001479290-21-000122
Filing Date
2021-05-10
Accepted
2021-05-10 16:10:22
Documents
16
Period of Report
2021-05-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rvnc-20210510.htm   iXBRL 8-K 36495
2 EX-99.1 rvncq121er8-k_exhibit991.htm EX-99.1 127079
8 newrevancelogo1.jpg GRAPHIC 11936
  Complete submission text file 0001479290-21-000122.txt   332962

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rvnc-20210510.xsd EX-101.SCH 2458
4 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rvnc-20210510_cal.xml EX-101.CAL 744
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rvnc-20210510_def.xml EX-101.DEF 1689
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rvnc-20210510_lab.xml EX-101.LAB 24275
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rvnc-20210510_pre.xml EX-101.PRE 12680
9 EXTRACTED XBRL INSTANCE DOCUMENT rvnc-20210510_htm.xml XML 11331
Mailing Address 7555 GATEWAY BLVD NEWARK CA 94560
Business Address 1222 DEMONBREUN STREET SUITE 1001 NASHVILLE TN 37203 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 21907252
SIC: 2834 Pharmaceutical Preparations